---
title: "MOTS-C"
canonical_url: https://peptidelibrary.app/library/mots-c
description: "A 16-amino-acid peptide encoded in the mitochondrial 12S ribosomal RNA gene, notable as an example of the mitochondrion signalling to the rest of the cell rather than only receiving instructions. It has been studied for effects on glucose utilisation and fatty-acid oxidation through AMPK activation in metabolic models. Circulating concentrations fall with age and rise with exercise. Research use only; no human trials have been published and it is not FDA-approved."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# MOTS-C

MOTS-C (also called Mitochondrial ORF of the 12S rRNA type-c) is a mitochondrial-derived peptide in the Mitochondrial Peptide class. MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S ribosomal RNA gene, an example of the mitochondria signalling to the rest of the cell rather than only receiving instructions.

A 16-amino-acid peptide encoded in the mitochondrial 12S ribosomal RNA gene, notable as an example of the mitochondrion signalling to the rest of the cell rather than only receiving instructions. It has been studied for effects on glucose utilisation and fatty-acid oxidation through AMPK activation in metabolic models. Circulating concentrations fall with age and rise with exercise. Research use only; no human trials have been published and it is not FDA-approved.

Also known as: Mitochondrial ORF of the 12S rRNA type-c.

Categories: Fat Loss, Longevity, GLP-1/Metabolic, Experimental.

## Classification

- Type: Mitochondrial-derived peptide / research
- Mechanism class: Mitochondrial Peptide
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S ribosomal RNA gene, an example of the mitochondria signalling to the rest of the cell rather than only receiving instructions. Under metabolic stress it translocates to the nucleus and acts as a transcriptional regulator, influencing adaptive nuclear gene expression. Its better-characterised action is on the folate-methionine cycle: by interfering with that pathway it causes accumulation of AICAR, an endogenous AMP mimetic, which activates AMP-activated protein kinase. AMPK activation increases glucose uptake and fatty-acid oxidation and shifts metabolism toward catabolic ATP generation. Circulating concentrations fall with age and rise with exercise. Human trials have not been published.

Targets: AMPK pathway.

Origin: Mitochondrial 12S rRNA short ORF peptide.

## Properties

- Sequence: MRWQEMGYIFYPRKLR
- Length: 16
- Molecular formula: C101H152N28O22S2
- Molecular weight: 2,174.6 g/mol
- CAS number: 1627580-64-6
- Half-life: ~2-4 hours

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 1
- Latest source: 2026

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. Human study (early or uncontrolled). Population: Adults with prediabetes and overweight or obesity (planned n=120). Insulin sensitivity. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07505745)
2. NCT03998514 — A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. Human study (early or uncontrolled). Population: Healthy non-obese subjects and subjects with non-alcoholic fatty liver disease (n=88). Safety, tolerability and pharmacokinetics. Research on a related compound, not this one. Limitations: Studied an analog, not MOTS-C itself [Source](https://clinicaltrials.gov/study/NCT03998514)
3. MOTS-c levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction. Arch Endocrinol Metab. 2025. 2025. Secondary report (review or programme summary), not a trial. Population: Adults with and without obesity. Association with inflammation, insulin resistance and endothelial dysfunction. Limitations: Reported in research, not a controlled trial. [Source](https://pubmed.ncbi.nlm.nih.gov/41004666/)
4. Reduced serum and skeletal muscle MOTS-c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction. Sci Rep. 2026. 2026. Secondary report (review or programme summary), not a trial. Population: Women with polycystic ovary syndrome. Association with mitochondrial dysfunction. Limitations: Reported in research, not a controlled trial. [Source](https://pubmed.ncbi.nlm.nih.gov/41680431/)
5. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. 2026. 2026. Preclinical: animal or lab study. Population: Animal and cell models. Mitochondrial bioenergetic health and efficiency via PGC-1α/AMPK. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/41520850/)

### Registered trials

- [NCT07505745](https://clinicaltrials.gov/study/NCT07505745)
- [NCT03998514](https://clinicaltrials.gov/study/NCT03998514)

## Safety

Side effects: Limited human data; Injection reactions.

Risks: Research-only.

Contraindications: Hypoglycemia risk.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

MOTS-C is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is MOTS-C?

A 16-amino-acid peptide encoded in the mitochondrial 12S ribosomal RNA gene, notable as an example of the mitochondrion signalling to the rest of the cell rather than only receiving instructions. It has been studied for effects on glucose utilisation and fatty-acid oxidation through AMPK activation in metabolic models. Circulating concentrations fall with age and rise with exercise. Research use only; no human trials have been published and it is not FDA-approved.

### What are the side effects of MOTS-C?

MOTS-C has no controlled human safety data, so its side-effect profile is not well established. Effects recorded on this profile include injection reactions. Cautions recorded on this profile: hypoglycemia risk. This is reference information, not medical advice.

### How does MOTS-C work?

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S ribosomal RNA gene, an example of the mitochondria signalling to the rest of the cell rather than only receiving instructions. Under metabolic stress it translocates to the nucleus and acts as a transcriptional regulator, influencing adaptive nuclear gene expression.

### Is MOTS-C FDA approved?

No. MOTS-C is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators.

### What is the half-life of MOTS-C?

Reported half-life for MOTS-C is ~2-4 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of MOTS-C?

MOTS-C has the sequence MRWQEMGYIFYPRKLR. Its molecular formula is C101H152N28O22S2.

### What peptides are similar to MOTS-C?

Compounds most often compared with MOTS-C include Humanin, Humanin-G (HNG), SS-20 and Elamipretide (SS-31). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne), 2023](https://pubmed.ncbi.nlm.nih.gov/36761202/)
- [MOTS-c Functionally Prevents Metabolic Disorders — Metabolites, 2023](https://pubmed.ncbi.nlm.nih.gov/36677050/)
- [Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases — Diabetes Metab J, 2023](https://pubmed.ncbi.nlm.nih.gov/36824008/)
- [Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c) — Diabetes Metab J, 2022](https://pubmed.ncbi.nlm.nih.gov/35656563/)
- [MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus — Bioessays, 2019](https://pubmed.ncbi.nlm.nih.gov/31378979/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
